|
|
|
|
|
Curative Effect of Lenvatinib Combined with Locoregional Therapy on PD-L1-positive Hepatocellular Carcinoma Patients with Type Ⅰ-Ⅲ Portal Vein Tumor Thrombus According to Cheng’s Classification |
| CHEN Long1, LIU Yujie1, TIAN Suqing2, WANG Cuiying1, HE Donglei3 |
| 1. Department of Oncology, Sanya Central Hospital, The Third People’s Hospital of Hainan Province, Sanya 572000, China; 2. Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, China; 3. Department of Gastrointestinal Cancer Surgery, The First Affiliated Hospital of Hainan Medical College, Haikou 570100, China |
|
|
|
|
Abstract Objective To compare curative effect between lenvatinib combined with locoregional therapy and locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng’s classification. Methods The patients in lenvatinib combined with locoregional therapy group received orally-administered lenvatinib at a dose of 12 mg qd for patients≥60 kg or 8 mg qd for patients<60 kg. The locoregional therapy group only received locoregional therapy. We retrospectively analyzed the clinical data and prognosis of two groups. Results The CR+PR were 78.1% and 53.6% in the combination group and locoregional therapy group, respectively (P<0.05). The response rate, disease control rate and overall survival of the combination group were higher than those in the locoregional therapy group (P<0.05). Conclusion The curative effect and overall survival of lenvatinib combined with locoregional therapy is better than locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng’s classification.
|
| Keywords
Hepatocellular carcinoma; Lenvatinib; Locoregional therapy; Portal vein tumor thrombus; PD-L1
|
|
|
|
Issue Date: 11 January 2022
|
|
[1] Zhang ZM, Lai EC, Zhang C, et al. The strategies for treating
primary hepatocellular carcinoma with portal vein tumor
thrombus[J]. Int J Surg, 2015, 20: 8-16.
[2] Katagiri S, Yamamoto M. Multidisciplinary treatments for
hepatocellular carcinoma with major portal vein tumor
thrombus[J]. Surg Today, 2014, 44(2): 219-226.
[3] 孙非凡, 李栋, 李华, 等. 程序性死亡配体1在索拉非尼耐药
肝癌细胞中的表达及功能[J]. 第二军医大学学报, 2018,
39(2): 152-158. [Sun FF, Li D, Li H, et al. Expression and
role of programmed cell death ligand-1 in sorafenib-resistant
hepatocellular carcinoma cells[J]. Di Er Jun Yi Da Xue Xue Bao,
2018, 39(2): 152-158.]
[4] 广东省抗癌协会肝癌专业委员会, 广东省医学会肝胆胰外科
学分会.肝细胞肝癌合并门静脉癌栓多学科团队综合治疗
广东专家共识(2015版)[J]. 中华消化外科杂志, 2015, 14(9):
694-701. [The Society of Liver Cancer of Guangdong Anti-cancer
Association,The Society of Hepato-Pancreato-Biliary Surgery of
Guangdong Medical Association. Cantonese expert consensus
on multidisciplinary team treatment for hepatocellular carcinoma
with portal vein tumor thrombus(2015 edition)[J]. Zhonghua Xiao
Hua Wai Ke Za Zhi, 14(9): 694-701.]
[5] National Comprehensive Cancer Network. NCCN clinical practice
guidelines in oncology (NCCN guidelines) Hepatocellular
Carcinoma(version 5.2020)[EB/OL]. https://www.nccn.org/
professionals/physician-gls/pdf/hepatobiliary-pdf.
[6] Llovet JM, Ricci S, Mazzaferm V, et al. Sorafenib in advanced
hepatocellular carcinoma[J]. N End J Med, 2008, 359(4): 378-390.
[7] Cheng AL, Kang YK, Chen Z, et al. Emcacy and safety of sorafenib
in patients in the Asia-Pacific region with advanced hepatocellular
carcinoma: a phase Ⅲ randomized, double-blind placebocontrolled
trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
[8] Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in
first-line treatment of patients with unresectable hepatocellular
carcinoma: a randomized phase 3 non-inferiority trial[J]. Lancet,
2018, 391(10126): 1163-1173.
[9] 黄海, 竺越, 保志军, 等. 肝动脉化疗栓塞术治疗老年肝癌病人
的疗效及预后影响因素分析[J]. 实用老年医学, 2019, 33(6):
577-581. [Huang H, Zhu Y, Bao ZJ, et al. Prognostic factors
of elderly patients with hepatocellular carcinoma undergoing
transcatheter arterial chemoembolization[J]. Shi Yong Lao Nian
Yi Xue, 2019, 33(6): 577-581.]
[10] 王洪云. 甲磺酸仑伐替尼联合TACE治疗中晚期原发性肝癌
的临床效果及安全性分析[J], 中国医学创新, 2020, 17(31):
6-9. [Wang HY. Analysis on the Clinical Effect and Safety of
Lenvatinib Mesilate Combined with TACE in the Treatment of
Patients with Metaphase and Advanced Primary Liver Cancer[J].
Zhongguo Yi Xue Chuang Xin, 2020, 17(31): 6-9.]
[11] 余紫珊, 何敏柯, 张耀军, 等. TAI 联合索拉非尼和单用索拉非
尼对伴门脉 主干或主分支癌栓的肝癌的疗效比较[J]. 广东医
学, 2018, 39(8): 1213-1222. [Yu ZS, He MK Y, Zhang YJ, et al.
Sorafenib combined with transcatheter arterial infusion versus
sorafenib alone for hepatocellular carcinoma with major portal
vein carcinoma thrombosis[J]. Guangdong Yi Xue, 2018, 39(8):
1213-1222.]
[12] Tsuchiya K, Kurosaki M, Kaneko S, et al. A nationwide multicenter
study in patients with unresectable hepatocellular carcinoma
treated with lenvatinib in real world practice in Japan[J]. J Clin
Oncol, 2019, 37(4-supl): 364.
[13] 袁冰, 王燕, 张金龙, 等. 仑伐替尼治疗经肝动脉化疗栓塞术
无效的中晚期肝细胞癌患者的临床观察[ J ] , 中华医学杂
志, 2020, 100(11): 833-836. [Yuan B, Wang Y, Zhang JL, et al.
Value of lenvatinib for the treatment of advanced hepatocellular
carcinoma[J]. Zhonghua Yi Xue Za Zhi, 2020, 100(11): 833-836.]
[14] 郅新, 高健, 郑晟旻, 等. 肝细胞癌经动脉化疗栓塞治疗的应用
现状与研究进展[J]. 中华普通外科杂志, 2019, 34(8): 742-744.
[Zhi X, Gao J, Zheng S, et al. Research progress of transcatheter
arterial chemoembolization treatment of hepatocellular
carcinoma[J]. Zhonghua Pu Tong Wai Ke Za Zhi, 2019, 34(8):
742-744.]
[15] 王慧, 顾红燕, 彭德明, 等. 仑伐替尼致不良反应文献分析[J]. 中
国新药杂志, 2020, 29(14): 1675-1680. [Wang H, Gu HY, Peng
DM, et al. Literature analysis of adverse drug reactions induced
by lenvatinib[J]. Zhongguo Xin Yao Za Zhi, 2020, 29(14):
1675-1680.] |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
